Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

News Center

6756758(2)-91.jpg

LaNova Medicines Completes USD 42 Million Series C1 Financing to Accelerate Clinical Progress and Innovation Platform Development

Learn More

All

2025

2024

2023

2022

2021

2020

CDE Granted LM-302 Breakthrough Therapy Designation for Claudin 18.2 positive GC/GEJ

2023-11-23

Learn More
LaNova Medicines Announces IND Approval of LM-24C5 by US FDA

2023-09-28

Learn More
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate

12 May, 2023, LaNova Medicines announced today it has entered into an exclusive license agreement with AstraZeneca for anti-GPRC5D ADC LM-305

2023-05-12

Learn More
LaNova Medicines and LegoChem evaluate novel first-in-class antibody drug conjugate candidate

2023-04-26

Learn More
LM-108 Receives Fast Track Designations for Cancer Treatments from US FDA

2023-04-21

Learn More
LaNova Medicines Announces the IND Approval of LM-101 by NMPA

Shanghai November 15th, 2022 – LaNova Medicines Ltd. announced that the investigational new drug (IND) of LM-101, an anti-SIRPα monoclonal antibody, has been approved by China NMPA.

2022-11-15

Learn More

4